NCCN treatment guidelines for advanced gastric cancer

Share This Post

The 2016 NCCN Clinical Guidelines for Gastric Cancer updated the systemic treatment plan for metastatic or locally advanced gastric cancer in the first edition (NCCN.2016.V1).

Among them, the DCF in the original first-line preferred plan was cancelled, the DCF improvement, ECF and ECF improvement were moved to other first-line programs, and docetaxel irinotecan in the other first-line programs was canceled.

The updated first-line preferred plan is 6 types in category 2 and 18 types in other types; the second-line preferred plan is 9 types in category 4 and 4 types in other types 3. It is hereby sorted as follows:

abbreviation:

D-Docetaxel, docetaxel;

E-Epirubicin, epirubicin;

F-Fluorouracil (5-FU), fluorouracil;

FOL-Folinic acid (leucovorin), calcium leucovorin;

I- Irinotecan, irinotecan;

O / OX-Oxaliplatin, Oxaliplatin;

P-Cisplatin, cisplatin (PDD);

R-Ramucirumab, Ramucirumab

T-Paclitaxel, paclitaxel;

X / XEL-Capecitabine, capecitabine;

FOLFOX-A series of chemotherapy regimens for the treatment of gastric or colorectal cancer composed of a combination of calcium folinate and fluorouracil combined with different doses of oxaliplatin is often called FOLFOX regimen

The chemotherapy regimen of XELOX-capecitabine combined with oxaliplatin is often referred to as the XELOX regimen

First-line preferred solution

HER2-neu overexpression of metastatic adenocarcinoma should be combined with trastuzumab for first-line non-anthracycline chemotherapy.

Specific plan: Trastuzumab intravenous injection for the first time at 8 mg / kg, day 1, followed by 6 mg / kg intravenous injection, 21 days / cycle; or for the first intravenous injection at 6 mg / kg, day 1, then 4 mg / kg intravenous injection, 14 days / cycle.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Limkato Korea’s first CAR T Cell therapy
CAR T-Cell therapy

Limkato: Korea’s first CAR T Cell therapy

South Korea is making significant strides in **CAR T cell therapy**, highlighted by the approval of **Limkato**, the first domestically developed CAR T therapy by **Curocell** in 2023. This milestone reduces reliance on foreign treatments and boosts Korea’s position in the global biotech industry. With strong government support and cutting-edge research, Korea is poised to advance CAR T therapies further, expanding applications and improving accessibility for cancer patients.

TIL therapy for melanoma in China
Melanoma

TIL therapy for melanoma in China

Tumor-Infiltrating Lymphocyte (TIL) therapy represents a promising advancement in the treatment of melanoma, particularly in cases where traditional treatments have failed. In China, the adoption of TIL therapy is gaining momentum, offering new hope to patients battling this aggressive form of skin cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟